Study #2020-1136
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Cyclophosphamide, Fludarabine, KITE-363
Description
The primary objective of Phase 1a of the study is to evaluate the safety of KITE-363 in participants with relapsed and/or refractory (r/r) B-cell lymphoma and to determine the dose level(s) for Phase 1b dose expansion. The primary objective of Phase 1b of the study is to evaluate the efficacy of KITE-363 in participants with r/r B-cell lymphoma as measured by the objective response rate (ORR) defined as complete response (CR) plus partial response (PR) rates.
Information and next steps
Disease:
Relapsed and/or Refractory B-cell Lymphoma
Study phase:
I
Physician name:
Loretta Nastoupil
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.